Business Context and Reporting Period
Relmada Therapeutics, Inc. filed a Form 8-K Current Report dated January 4, 2019, covering events occurring on January 1, 2019. The filing details a change in the company's corporate headquarters and the execution of a new lease agreement.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed is the monthly rental fee for the new premises, which is $7,513.
Material Changes
- New Lease Agreement: Effective January 1, 2019, the Company entered into a lease with 880 Third Avenue Tenant LLC for space at 880 3rd Ave, 12th Floor, New York, NY 10022.
- Lease Terms: The agreement expires on December 31, 2019, with a monthly rental fee of $7,513.
- Termination of Prior Agreement: Effective January 1, 2019, the Company terminated its previous lease dated May 2, 2017, with Regus Management Group, LLC for space at 750 Third Avenue, 9th Floor, New York, NY 10017.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly a notification of the change in corporate headquarters and the associated lease transactions.
Investor Verification Checklist
- Verify the total cost of the new lease relative to the company's cash position in the upcoming Form 10-Q.
- Confirm the operational impact of relocating from 750 Third Avenue to 880 3rd Avenue.
- Review the full text of the Lease Agreement when it is filed as an exhibit to the Form 10-Q for the quarter ended December 31, 2018.